Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2026
ECG Markers of Positive Drug Challenge With Ajmaline in Patients With Brugada Syndrome.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tülümen Erol, Kruska Mathieu, Wuerfel Sara, Kohl Maximilian, Liebe Volker, Akin Ibrahim, Kuschyk Juergen, Duerschmied Daniel, Borggrefe Martin, Rudic Boris
Аннотация
BACKGROUND: Ajmaline challenge (AC) is used for diagnosing suspected Brugada syndrome (BS) in patients with unexplained syncope, survived cardiac arrest, or for family screening.
PURPOSE: To evaluate baseline ECG markers predicting a positive AC in the absence of a spontaneous diagnostic Brugada ECG.
METHODS: Baseline ECGs of 221 consecutive patients undergoing AC (up to 1 mg/kg bodyweight) were analyzed. ECGs from positive and negative tests were compared, with Q-, R-, S-, J-, and T-wave amplitudes and intervals measured in all 12 leads.
RESULTS: 221 patients underwent AC; the cohort was 71% male, and 7% had survived cardiac arrest. AC was positive in 93 patients (42%). Prominent S-waves in lead II and J-waves in V1 predicted a positive AC (S-wave duration: 36 vs. 22 ms, p < 0.01; J-wave amplitude V1: 0.06 vs. 0.01 mV, p < 0.001). ROC analysis confirmed discriminative value for S-wave duration in lead II (AUC 0.79) and J-wave amplitude in V1 (AUC 0.71). A cut off of ≥ 19 ms for S-wave duration in lead II showed 96% sensitivity for a positive test (OR 17.3, p < 0.001). J-wave amplitude in V1 ≥ 0.05 mV was also significantly associated (OR 5.4, p < 0.001).
CONCLUSION: In patients without a spontaneous diagnostic Brugada ECG, prominent S-waves in lead II and J-waves in V1 are subtle electrical abnormalities that help identify patients and family members with a higher likelihood of positive AC.
PURPOSE: To evaluate baseline ECG markers predicting a positive AC in the absence of a spontaneous diagnostic Brugada ECG.
METHODS: Baseline ECGs of 221 consecutive patients undergoing AC (up to 1 mg/kg bodyweight) were analyzed. ECGs from positive and negative tests were compared, with Q-, R-, S-, J-, and T-wave amplitudes and intervals measured in all 12 leads.
RESULTS: 221 patients underwent AC; the cohort was 71% male, and 7% had survived cardiac arrest. AC was positive in 93 patients (42%). Prominent S-waves in lead II and J-waves in V1 predicted a positive AC (S-wave duration: 36 vs. 22 ms, p < 0.01; J-wave amplitude V1: 0.06 vs. 0.01 mV, p < 0.001). ROC analysis confirmed discriminative value for S-wave duration in lead II (AUC 0.79) and J-wave amplitude in V1 (AUC 0.71). A cut off of ≥ 19 ms for S-wave duration in lead II showed 96% sensitivity for a positive test (OR 17.3, p < 0.001). J-wave amplitude in V1 ≥ 0.05 mV was also significantly associated (OR 5.4, p < 0.001).
CONCLUSION: In patients without a spontaneous diagnostic Brugada ECG, prominent S-waves in lead II and J-waves in V1 are subtle electrical abnormalities that help identify patients and family members with a higher likelihood of positive AC.